Physicians’ Attitudes on Management of Osteopenia in South Korea
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Background: Osteopenia patients have a risk of fracture and may develop osteoporosis. We investigated physicians’ management of osteopenia patients in South Korea. Methods: A survey was conducted using a questionnaire including 6 items: (1) do you think anti-osteoporosis medications are necessary in osteopenia patients?; (2) what is your preference to manage osteopenia patients, except for anti-osteoporosis medications?; (3) what is your indication for the anti-osteoporosis medication in osteopenia patients?; (4) what kind of anti-osteoporosis medication do you prefer to treat osteopenia patients?; (5) do you use bisphosphonates?; and (6) if not, what is the reason for not using?. Results: Among the 173 participants, 150 (86.7%) replied that anti-osteoporosis medications were necessary in osteopenia patients. Indications for the medication were (1) past medical history of pathologic fracture in 85 (49.1%); (2) T-score <-2.5 on dual energy X-ray absorptiometry in 73 (42.2%); (3) previous history of osteoporosis in 44 (25.4%); (4) risk of fracture according to fracture risk assessment tool in 34 (19.7%); and (5) progressive bone loss in 31 (17.9%). One hundred and sixteen (67.1%) favored bisphosphonates, 93 (53.8%) selective estrogen-receptor modulator, and 24 (13.9%) hormone replacement therapy. Thirty-one (17.9%) replied that they do not use bisphosphonates due to (1) restricted reimbursement by the health insurance in 24 (77.4%); and (2) bisphosphonate-related complications in 19 (61.3%). Conclusions: Most respondents (86.7%) thought anti-osteoporosis medications were necessary in osteopenia patients, but 17.9% of the respondents did not use bisphosphonates. Restricted reimbursement by the national health insurance was the major obstacle against the use of bisphosphonates.
Abstract
Background: Osteopenia patients have a risk of fracture and may develop osteoporosis. We investigated physicians’ management of osteopenia patients in South Korea. Methods: A survey was conducted using a questionnaire including 6 items: (1) do you think anti-osteoporosis medications are necessary in osteopenia patients?; (2) what is your preference to manage osteopenia patients, except for anti-osteoporosis medications?; (3) what is your indication for the anti-osteoporosis medication in osteopenia patients?; (4) what kind of anti-osteoporosis medication do you prefer to treat osteopenia patients?; (5) do you use bisphosphonates?; and (6) if not, what is the reason for not using?. Results: Among the 173 participants, 150 (86.7%) replied that anti-osteoporosis medications were necessary in osteopenia patients. Indications for the medication were (1) past medical history of pathologic fracture in 85 (49.1%); (2) T-score <-2.5 on dual energy X-ray absorptiometry in 73 (42.2%); (3) previous history of osteoporosis in 44 (25.4%); (4) risk of fracture according to fracture risk assessment tool in 34 (19.7%); and (5) progressive bone loss in 31 (17.9%). One hundred and sixteen (67.1%) favored bisphosphonates, 93 (53.8%) selective estrogen-receptor modulator, and 24 (13.9%) hormone replacement therapy. Thirty-one (17.9%) replied that they do not use bisphosphonates due to (1) restricted reimbursement by the health insurance in 24 (77.4%); and (2) bisphosphonate-related complications in 19 (61.3%). Conclusions: Most respondents (86.7%) thought anti-osteoporosis medications were necessary in osteopenia patients, but 17.9% of the respondents did not use bisphosphonates. Restricted reimbursement by the national health insurance was the major obstacle against the use of bisphosphonates.
참고문헌 (22)
- Zhang J, "Osteopenia : debates and dilemmas", Curr Rheumatol Rep, 15, pp.384~ (2013)
- Black DM, "Axial and appendicular bone density predict fractures in older women", J Bone Miner Res, 7, pp.633~638 (1992)
- Gourlay ML, "Bone-density testing interval and transition to osteoporosis in older women", N Engl J Med, 366, pp.225~233 (2012)
- Hillier TA, "WHO absolute fracture risk models(FRAX) : do clinical risk factors improve fracture prediction in older women without osteoporosis", J Bone Miner Res, 26, pp.1774~1782 (2011)
- Cranney A, "Low bone mineral density and fracture burden in postmenopausal women", CMAJ, 177, pp.575~580 (2007)
- Kanis JA, "Diagnosis of osteoporosis", Osteoporos Int, 7(Suppl 3), pp.S108~S116 (1997)
- Siris ES, "Bone mineral density thresholds for pharmacological intervention to prevent fractures", Arch Intern Med, 164, pp.1108~1112 (2004)
- 김하영, "Healthcare Costs of Osteoporotic Fracture in Korea: Information from the National Health Insurance Claims Database, 2008-2011", 대한골대사학회지, 24(2), pp.125~133 (2017), 대한골대사학회[DOI]
- Zhang J, "Long-term safety concerns of antiresorptive therapy", Rheum Dis Clin North Am, 37, pp.387~400 (2011)
- Qaseem A, "Treatment of low bone density or osteoporosis to prevent fractures in men and women : A clinical practice guideline update from the American college of physicians", Ann Intern Med, 166, pp.818~839 (2017)
- 박은정, "Prevalence of Osteoporosis in the Korean Population Based on Korea National Health and Nutrition Examination Survey (KNHANES), 2008--2011", Yonsei Medical Journal, 55(4), pp.1049~1057 (2014), 연세대학교의과대학[DOI]
- 유제현, "Osteoporotic Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research", 대한골대사학회지, 22(4), pp.175~181 (2015), 대한골대사학회
- Eriksen EF, "Treatment of osteopenia", Rev Endocr Metab Disord, 13, pp.209~223 (2012)
- Gu JM, "The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia : 1-year data", Acta Pharmacol Sin, 36, pp.841~846 (2015)
- Reid IR, "Fracture prevention with zoledronate in older women with osteopenia", N Engl J Med, 379, pp.2407~2416 (2018)
- Gallagher JC, "Moderation of the daily dose of HRT : prevention of osteoporosis", Maturitas, 33(Suppl 1), pp.S57~S63 (1999)
- Korthoewer D, "Osteoporosis management and the utilization of FRAX® : a survey amongst health care professionals of the Asia-Pacific", Arch Osteoporos, 7, pp.193~200 (2012)
- 하용찬, "Physicians’ Attitudes to Contemporary Issues on Osteoporosis Management in Korea", 대한골대사학회지, 21(2), pp.139~145 (2014), 대한골대사학회
- 박소영, "Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis", 대한골대사학회지, 25(4), pp.195~211 (2018), 대한골대사학회
- Ilyas Z, "Rare adverse effects of bisphosphonate therapy", Curr Opin Endocrinol Diabetes Obes, 26, pp.335~338 (2019)
- Won Seok-Hyung, "Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort", Journal of Korean Medical Science, 35(25), pp.1~12 (2020), 대한의학회[DOI]
- Compston JE, "The risks and benefits of HRT", J Musculoskelet Neuronal Interact, 4, pp.187~190 (2004)